Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

About the company

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

235

CEO

Cedric Francois

Exchange

NASDAQ

Website

http://www.apellis.com

$NoneM

Total Revenue

235

Employees

$2B

Market Capitalization

-5.22

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

Operating Margin (in %)

Total operating margin

Net Margin (in %)

Total net margin

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Johnson & Johnson JNJ 377376.69 82729.00 6.06 21.99 20.75
Merck & Co., Inc. MRK 202149.48 48081.00 7.59 19.94 21.10
Pfizer Inc. PFE 194670.90 50660.00 2.95 12.32 31.17
Eli Lilly & Co. LLY 150432.66 23087.00 51.05 26.52 23.97
AbbVie, Inc. ABBV 146737.92 34057.00 -23.49 17.50 24.65
Bristol Myers Squibb Co. BMY 110414.38 31006.00 2.68 93.87 3.08
Repligen Corp. RGEN 6459.15 286.00 6.19 281.44 8.11
Reata Pharmaceuticals, Inc. RETA 4893.35 20.00 23.18 -15.74 -150.30
Nektar Therapeutics NKTR 4139.52 137.00 3.23 -9.01 -335.62
Biohaven Pharmaceutical Holding Co. Ltd. BHVN 3702.40 1.00 34.23 -5.66 None
Allakos, Inc. ALLK 3144.30 None 6.83 -33.62 None
Karuna Therapeutics, Inc. KRTX 2853.24 None 7.45 -70.35 None
ADC Therapeutics SA ADCT 2756.70 2.00 32.52 -23.63 None
Turning Point Therapeutics, Inc. TPTX 2316.60 None 6.97 -19.38 None
IGM Biosciences, Inc. IGMS 2244.09 None 9.89 -41.37 None
Apellis Pharmaceuticals, Inc. APLS 2175.36 None 9.61 -5.22 None
OPKO Health, Inc. OPK 2155.86 891.00 1.53 -7.37 -32.92
Ra Pharmaceuticals, Inc. RARX 2111.78 3.00 8.68 -20.78 -585.71
Springworks Therapeutics, Inc. SWTX 1743.65 None 5.66 -27.97 None
Principia Biopharma, Inc. PRNB 1568.00 30.00 5.58 -22.31 -242.01
Y-mAbs Therapeutics, Inc. YMAB 1551.78 None 9.51 -16.84 None
Zymeworks, Inc. ZYME 1511.16 26.00 3.14 -8.91 -629.37
Akcea Therapeutics, Inc. AKCA 1370.61 341.00 2.81 -48.72 -8.59
Kiniksa Pharmaceuticals Ltd. KNSA 1305.15 None 6.76 -10.79 None
Tricida, Inc. TCDA 1298.01 None 6.67 -6.15 None
Arcutis Biotherapeutics, Inc. ARQT 1184.37 None 5.05 -18.94 None
Odonate Therapeutics, Inc. ODT 1163.48 None 9.53 -10.34 None
Athenex, Inc. ATNX 1070.16 123.00 6.56 -9.94 -87.86
Phibro Animal Health Corp. PAHC 1068.87 818.00 5.40 28.97 4.49
Akero Therapeutics, Inc. AKRO 957.58 None 8.00 -18.87 None
Constellation Pharmaceuticals, Inc. CNST 927.36 None 3.86 -9.99 None
Oric Pharmaceuticals, Inc. ORIC 838.04 None -9.10 -27.71 None
G1 Therapeutics, Inc. GTHX 818.52 1.00 3.54 -6.24 None
Gossamer Bio, Inc. GOSS 802.76 None 3.26 -4.04 None
Phathom Pharmaceuticals, Inc. PHAT 789.50 None 4.38 -2.90 None
Aprea Therapeutics, Inc. APRE 768.60 None 6.80 -22.73 None
Krystal Biotech, Inc. KRYS 760.75 None 4.44 -36.68 None
Quanterix Corp. QTRX 752.76 60.00 6.64 -17.21 -71.52
Provention Bio, Inc. PRVB 669.94 None 10.60 -15.13 None
Provention Bio, Inc. PRVB 651.88 None 10.31 -14.72 None
Keros Therapeutics, Inc. KROS 644.40 8.00 -29.11 -30.34 -285.35
Amneal Pharmaceuticals, Inc. AMRX 619.24 1679.00 4.26 -2.84 -11.85
Arcturus Therapeutics Holdings, Inc. ARCT 605.28 19.00 56.10 -21.76 -151.34
Oyster Point Pharma, Inc. OYST 596.40 None 5.99 -10.36 None
Mirum Pharmaceuticals, Inc. MIRM 503.75 None 3.28 -7.44 None
SIGA Technologies, Inc. SIGA 489.54 19.00 5.48 -24.87 -94.00
Imara, Inc. IMRA 483.82 None 4.67 -13.75 None
Satsuma Pharmaceuticals, Inc. STSA 463.25 None 4.56 -12.73 None
Biospecifics Technologies Corp. BSTC 436.94 40.00 3.55 18.69 61.80
DURECT Corp. DRRX 416.64 28.00 32.00 -17.23 -82.94
Fulcrum Therapeutics, Inc. FULC 410.55 1.00 6.92 -5.95 None
Crinetics Pharmaceuticals, Inc. CRNX 406.56 1.00 5.13 -6.97 -447.78
Ocular Therapeutix, Inc. OCUL 396.48 6.00 -48.59 -4.32 None
89bio, Inc. ETNB 386.40 None 4.77 -5.99 None
Relmada Therapeutics, Inc. RLMD 385.02 0.00 5.74 -32.17 -877.66
Kala Pharmaceuticals, Inc. KALA 380.16 6.00 4.16 -4.14 None
TCR2 Therapeutics, Inc. TCRR 373.20 None 2.55 -37.02 None
Osmotica Pharmaceuticals Plc OSMT 349.38 232.00 2.65 -1.27 -115.44
Ovid Therapeutics, Inc. OVID 323.55 None 7.65 -4.96 None
Urovant Sciences Ltd. UROV 315.00 None -5.59 -2.18 None
Aeglea Biotherapeutics, Inc. AGLE 298.98 4.00 9.44 -3.73 -523.27
HOOKIPA Pharma, Inc. HOOK 280.28 13.00 2.54 -6.20 -333.02
IDEAYA Biosciences, Inc. IDYA 274.60 None 4.17 -6.30 None
AMAG Pharmaceuticals, Inc. AMAG 273.70 321.00 1.05 -0.74 -115.05
Lannett Co., Inc. LCI 270.56 542.00 0.92 -8.90 -5.77
Verrica Pharmaceuticals, Inc. VRCA 257.50 None 4.70 -8.44 None
Spero Therapeutics, Inc. SPRO 254.03 12.00 3.34 -3.12 -656.72
Gritstone Oncology, Inc. GRTS 236.88 4.00 2.12 -2.27 None
Kaleido Biosciences, Inc. KLDO 234.00 None 8.30 -3.20 None
KalVista Pharmaceuticals, Inc. KALV 233.46 12.00 2.58 -7.21 -263.38
Veru, Inc. VERU 218.40 39.00 7.30 -22.40 -25.53
LogicBio Therapeutics, Inc. LOGC 191.36 1.00 5.78 -4.50 None
Galera Therapeutics, Inc. GRTX 180.25 None 3.37 -2.74 None
Liquidia Technologies, Inc. LQDA 171.38 8.00 10.12 -3.48 -602.17
Sutro Biopharma, Inc. STRO 171.12 41.00 3.25 -2.81 -148.06
Protara Therapeutics, Inc. TARA 168.06 None 2.53 -10.90 None
Avenue Therapeutics, Inc. ATXI 167.52 532.00 30.79 -11.51 26.69
Applied Therapeutics, Inc. APLT 165.75 14.00 3.58 -63.75 -19.41
Evolus, Inc. EOLS 164.40 45.00 2.95 -1.62 -217.51
Evelo Biosciences, Inc. EVLO 160.96 None 4.12 -1.84 None
Cyclerion Therapeutics, Inc. CYCN 156.60 6.00 1.97 -1.51 None
Tyme Technologies, Inc. TYME 148.35 None 8.60 -6.79 None
Harrow Health, Inc. HROW 137.28 51.00 8.80 -5.56 -47.54
Trevi Therapeutics, Inc. TRVI 137.07 None 2.91 -4.67 None
scPharmaceuticals, Inc. SCPH 136.04 119.00 3.48 -4.34 -27.05
Lyra Therapeutics, Inc. LYRA 133.32 1.00 -1.13 -7.99 -491.16
Aquestive Therapeutics, Inc. AQST 131.88 49.00 -7.60 -1.88 -139.64
PhaseBio Pharmaceuticals, Inc. PHAS 127.31 2.00 2.36 -2.66 None
Mustang Bio, Inc. MBIO 122.40 None 2.86 -2.49 None
NeuBase Therapeutics, Inc. NBSE 121.24 None 50.94 -2.71 None
TFF Pharmaceuticals, Inc. TFFP 117.61 None 4.55 -3.03 None
Immunic, Inc. IMUX 117.40 None 3.45 -53.36 None
Ayala Pharmaceuticals, Inc. AYLA 116.40 3.00 -2.74 -5.64 -679.19
Eton Pharmaceuticals, Inc. ETON 99.36 1.00 10.82 -4.97 None
Milestone Pharmaceuticals, Inc. MIST 93.00 None 0.92 -1.49 None
Checkpoint Therapeutics, Inc. CKPT 79.60 2.00 6.86 -3.43 -949.53
EyePoint Pharmaceuticals, Inc. EYPT 79.57 26.00 5.62 -1.62 -196.30
Clearside Biomedical, Inc. CLSD 79.54 6.00 10.21 -4.51 -293.61
Xeris Pharmaceuticals, Inc. XERS 78.12 4.00 3.87 -0.60 None
Corvus Pharmaceuticals, Inc. CRVS 75.40 None 1.21 -1.60 None
Baudax Bio, Inc. BXRX 72.00 None -1.96 -1.03 None
Navidea Biopharmaceuticals, Inc. NAVB 68.34 1.00 -50.25 -6.18 -65.13
BiomX, Inc. PHGE 65.45 None 1.72 -1.53 None
Assertio Therapeutics, Inc. ASRT 59.04 192.00 1.02 -0.36 -83.99
Genprex, Inc. GNPX 57.57 None 4.89 -4.21 None
Aridis Pharmaceuticals, Inc. ARDS 56.97 1.00 -23.44 -1.95 -851.00
Aerpio Pharmaceuticals, Inc. ARPO 51.66 20.00 1.56 -2.74 -51.58
Menlo Therapeutics, Inc. MNLO 49.01 2.00 4.12 -0.52 -483.51
Eyenovia, Inc. EYEN 45.60 None 4.60 -2.23 None
Edesa Biotech, Inc. EDSA 44.82 0.00 6.38 -0.47 -395.23
Moleculin Biotech, Inc. MBRX 42.69 None 3.71 -4.64 None
Akari Therapeutics Plc AKTX 36.18 None -33.50 -2.01 None
Oncternal Therapeutics, Inc. ONCT 35.75 3.00 4.58 -1.42 -225.89
Allena Pharmaceuticals, Inc. ALNA 35.42 None 4.67 -0.81 None
Mannatech, Inc. MTEX 34.08 156.00 1.44 7.68 3.45
AgeX Therapeutics, Inc. AGE 33.78 2.00 -44.45 -2.78 -658.11
CNS Pharmaceuticals, Inc. CNSP 33.12 None 5.75 -6.09 None
Citius Pharmaceuticals, Inc. CTXR 32.94 None 2.44 -1.91 None
Acer Therapeutics, Inc. ACER 32.50 3.00 2.37 -1.25 -274.69
Aileron Therapeutics, Inc. ALRN 32.48 None 4.46 -1.22 None
Adamis Pharmaceuticals Corp. ADMP 31.32 22.00 1.20 -1.06 -140.33
Annovis Bio, Inc. ANVS 30.10 None 2.76 -23.89 None
Millendo Therapeutics, Inc. MLND 25.80 0.00 0.61 -0.55 None
Hoth Therapeutics, Inc. HOTH 25.00 None 6.94 -2.78 None
Spring Bank Pharmaceuticals, Inc. SBPH 23.20 0.00 0.88 -0.89 None
Akorn, Inc. AKRX 22.68 721.00 -1.20 -0.06 -55.64
Daré Bioscience, Inc. DARE 18.81 1.00 8.25 -1.13 None
ProPhase Labs, Inc. PRPH 16.80 9.00 1.52 -5.60 -31.15
Teligent, Inc. TLGT 14.40 60.00 -0.49 -0.36 -71.80
Teligent, Inc. TLGT 14.40 60.00 -0.49 -0.36 -71.80
Novan, Inc. NOVN 14.21 5.00 -3.27 -0.45 -602.34
Adial Pharmaceuticals, Inc. ADIL 13.80 None 3.37 -1.82 None
Titan Pharmaceuticals, Inc. TTNP 12.00 4.00 5.00 -0.67 -437.91
PDS Biotechnology Corp. PDSB 11.69 None 1.29 -0.46 None
Novus Therapeutics, Inc. NVUS 7.39 None 0.63 -0.35 None
Brickell Biotech, Inc. BBI 5.05 5.00 1.66 -0.07 -432.19
BioStar Pharmaceuticals, Inc. BSPM 0.21 0.00 0.01 0.10 294.01

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

2d ago, source: YAHOO!

PRINCE study enrolled 53 patients. WALTHAM, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today ...

Brokers Set Expectations for Apellis Pharmaceuticals Inc’s FY2021 Earnings (NASDAQ:APLS)

1d ago, source: modernreaders.com

Cantor Fitzgerald issued their FY2021 earnings estimates for shares of Apellis Pharmaceuticals in a report released on ...

Meeder Asset Management Inc. Cuts Stake in Apellis Pharmaceuticals Inc (NASDAQ:APLS)

5d ago, source: theenterpriseleader.com

Meeder Asset Management Inc. reduced its position in Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 46.2% during the 1st ...

BRIEF-Apellis Completes Enrollment In Phase 3 Study Of Pegcetacoplan

2d ago, source: Reuters

APELLIS COMPLETES ENROLLMENT IN PHASE 3 STUDY OF PEGCETACOPLAN IN TREATMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINU ...

Deutsche Bank AG Grows Stock Holdings in Apellis Pharmaceuticals Inc (NASDAQ:APLS)

13d ago, source: theenterpriseleader.com

Deutsche Bank AG increased its position in Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 12.4% in the 1st quarter, according ...

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

2d ago, source: Business Insider

July 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the completion of enrollment ...

BRIEF-Apellis Completes Enrollment In Phase 3 Study Of Pegcetacoplan

2d ago, source: Reuters

APELLIS PHARMACEUTICALS INC - PLANS TO SUBMIT MARKETING APPLICATIONS FOR PEGCETACOPLAN FOR TREATMENT OF PNH BOTH IN U.S., EU IN H2 2020 Source text for Eikon: Further company coverage: Our ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.